Formuepleje A S Has $1.33 Million Stock Position in Intuitive Surgical, Inc. $ISRG

Formuepleje A S reduced its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 70.8% in the 2nd quarter, Holdings Channel.com reports. The institutional investor owned 3,354 shares of the medical equipment provider’s stock after selling 8,141 shares during the quarter. Formuepleje A S’s holdings in Intuitive Surgical were worth $1,334,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Brown Financial Advisors raised its holdings in Intuitive Surgical by 18.3% in the 2nd quarter. Brown Financial Advisors now owns 2,293 shares of the medical equipment provider’s stock worth $912,000 after acquiring an additional 355 shares during the period. Advus Financial Partners LLC bought a new stake in Intuitive Surgical during the second quarter valued at about $208,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Intuitive Surgical during the second quarter valued at about $14,316,000. California State Teachers Retirement System grew its position in shares of Intuitive Surgical by 39,531.1% in the second quarter. California State Teachers Retirement System now owns 213,725,958 shares of the medical equipment provider’s stock valued at $84,994,539,000 after purchasing an additional 213,186,670 shares during the last quarter. Finally, Tanager Wealth Management LLP grew its position in shares of Intuitive Surgical by 70.2% in the second quarter. Tanager Wealth Management LLP now owns 749 shares of the medical equipment provider’s stock valued at $298,000 after purchasing an additional 309 shares during the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Gary Loeb sold 400 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total transaction of $151,600.00. Following the completion of the sale, the executive vice president owned 5,320 shares in the company, valued at $2,016,280. The trade was a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Mark Brosius sold 77 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $375.57, for a total transaction of $28,918.89. Following the completion of the transaction, the executive vice president owned 881 shares in the company, valued at $330,877.17. This represents a 8.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 11,635 shares of company stock valued at $4,640,172. 0.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ISRG. The Goldman Sachs Group set a $558.00 price objective on Intuitive Surgical in a research report on Wednesday, May 27th. Leerink Partners lowered their target price on Intuitive Surgical from $573.00 to $454.00 and set an “outperform” rating on the stock in a report on Friday, July 17th. Citigroup cut their price target on Intuitive Surgical from $590.00 to $500.00 and set a “buy” rating for the company in a report on Friday, July 17th. JPMorgan Chase & Co. reduced their price objective on Intuitive Surgical from $550.00 to $450.00 and set an “overweight” rating for the company in a research report on Friday, July 17th. Finally, Piper Sandler restated an “overweight” rating on shares of Intuitive Surgical in a research note on Friday, August 21st. Twenty-two analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average price target of $508.68.

Intuitive Surgical Stock Performance

Shares of ISRG stock opened at $366.70 on Monday. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88. The stock has a market cap of $129.55 billion, a price-to-earnings ratio of 42.00, a P/E/G ratio of 2.77 and a beta of 1.47. The firm has a fifty day moving average of $381.44 and a 200-day moving average of $428.20.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, July 16th. The medical equipment provider reported $2.80 earnings per share for the quarter, beating the consensus estimate of $2.48 by $0.32. The business had revenue of $2.89 billion for the quarter, compared to analyst estimates of $2.83 billion. Intuitive Surgical had a net margin of 28.45% and a return on equity of 16.91%. The firm’s revenue was up 18.4% on a year-over-year basis. During the same period in the previous year, the business earned $1.81 EPS. On average, sell-side analysts predict that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current year.

About Intuitive Surgical

Intuitive Surgical, founded in 1995 and headquartered in Sunnyvale, California, is a medical technology company focused on the design, manufacture and service of robotic-assisted surgical systems. The company is best known for its da Vinci surgical systems, which enable minimally invasive procedures by translating a surgeon’s hand movements into finer, scaled motions of small instruments inside the patient. Intuitive’s business centers on supplying hospitals and surgical centers with systems, instruments and related technologies that aim to improve precision, visualization and control in the operating room.

In addition to its core surgical platforms, Intuitive markets a portfolio of reusable and disposable instruments, accessories, and proprietary software, and provides training, servicing and clinical support to its customers.